Patents Examined by Amanda P. Wood
  • Patent number: 7413871
    Abstract: The invention relates to a method for evaluating a pancreas as a source of therapeutically useful islets. A scoring system is set forth whereby 5 criteria are listed. If three criteria are positive, then the pancreas is a suitable source of therapeutically useful islets.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: August 19, 2008
    Assignee: The Rogosin Institute
    Inventors: Lawrence Gazda, Barry Smith, Albert Rubin
  • Patent number: 7405078
    Abstract: By using a bed material for cell culture having a surface composed of two domains of domain A coated with a temperature-responsive polymer and domain B composed of any one or a combination of a domain coated with a polymer having high affinity with cells, a domain coated with the temperature-responsive polymer in an amount different from the amount of the temperature-responsive polymer of domain A, and a domain coated with a polymer which responds to a temperature different from the temperature to which domain A responds, a method for the co-culture of a plurality of kinds of cells which has heretofore been difficult becomes possible.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: July 29, 2008
    Assignee: Cellseed Inc.
    Inventors: Teruo Okano, Masayuki Yamato, Akihiko Kikuchi
  • Patent number: 7384760
    Abstract: The present invention relates to methods for assaying inhibitors for S-adenosylhomocysteine (SAH) hydrolases and assaying inhibitors for S-adenosylmethionine (SAM)-dependent methyltransferases. The methods are amenable for use in high throughput formats. Kits for performing the methods are also provided.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: June 10, 2008
    Assignee: General Atomics
    Inventors: Chong-Sheng Yuan, Qi-Zhuang Ye, Sheng-Xue Xie
  • Patent number: 7381536
    Abstract: The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.
    Type: Grant
    Filed: March 1, 2005
    Date of Patent: June 3, 2008
    Inventor: Paul A. Gurbel
  • Patent number: 7371517
    Abstract: Isolated non-naturally occurring populations of spermatozoa (15) having high purity and technologies to differentiate spermatozoa (28) based on characteristics such as mass, volume, orientation, or emitted light including methods of analysis and apparatus such as beam shaping optics (30) and detectors (32).
    Type: Grant
    Filed: May 9, 2001
    Date of Patent: May 13, 2008
    Assignee: XY, Inc.
    Inventors: Kenneth M. Evans, Erik B. van Munster
  • Patent number: 7351548
    Abstract: The invention concerns a culture medium for isolating bacteria of Listeria genus, in particular L. monocytogenes, characterized in that it comprises in a Listeria culture medium, at least a specific agent for identifying ?-mannosidase for use in solid medium.
    Type: Grant
    Filed: January 4, 2002
    Date of Patent: April 1, 2008
    Inventor: Alain Rambach
  • Patent number: 7335352
    Abstract: Screening assays that allow for the identification of agents that increase acyl homoserine lactone (AHL) acylase expression and/or AHL acylase activity in ?-proteobacteria such as Pseudomonas aeruginosa. Such agents are useful, for example, for inhibiting quorum sensing activity of such bacteria by increasing degradation of long chain, but not short chain, AHLs and, therefore, can be useful for treating infections by such bacteria.
    Type: Grant
    Filed: June 3, 2004
    Date of Patent: February 26, 2008
    Assignee: California Institute of Technology
    Inventors: Jared Leadbetter, Jean J. Huang
  • Patent number: 7323318
    Abstract: Image analysis methods and apparatus are used for distinguishing live and dead cells. The methods may involve segmenting an image to identify the region(s) occupied by one or more cells and determining the presence of a particular live-dead indicator feature within the region(s). In certain embodiments, the indicator feature is a cytoskeletal component such as tubulin. Prior to producing an image for analysis, cells may be treated with a marker that highlights the live-dead indicator in the image. In the case of tubulin, the marker will co-locate with tubulin and provide a signal that is captured in the image (e.g., a fluorescent emission).
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: January 29, 2008
    Assignee: Cytokinetics, Inc.
    Inventors: Jinhong Fan, Vadim Kutsyy, Eugeni A. Vaisberg
  • Patent number: 7323317
    Abstract: An analytical fluorometric method and a kit for use in such method are disclosed for assessing the presence of alkaline sphingomyelinase (SMase) in the stool of a patient in need of such an assessment since alkaline SMase is a marker of serious pathological states, such as colon cancer.
    Type: Grant
    Filed: March 1, 2007
    Date of Patent: January 29, 2008
    Assignee: VSL Pharmaceuticals, Inc.
    Inventor: Claudio De Simone
  • Patent number: 7319017
    Abstract: An in vitro method for identifying subjects at risk of heart failure following a Myocardial Infarction comprising analyzing the concentration of Matrix Metalloproteinase-9 in a bodily sample from a subject who has suffered a Myocardial Infarction and comparing this concentration with a reference for concentrations of Matrix Metalloproteinase-9 in individuals who have not suffered a Myocardial Infarction; wherein a raised concentration of Matrix Metalloproteinase-9 in the bodily sample from a subject who has suffered a Myocardial Infarction suggests the subject is at risk of heart failure.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: January 15, 2008
    Assignee: Centre de Recherche Public de la Santé
    Inventor: Daniel R. Wagner
  • Patent number: 7316913
    Abstract: The invention relates to a method for the investigation of intercellular communication and intercellular transport, wherein after singularisation cells are investigated for membrane tubes which contain F-actin and myosin, have a diameter of 50 to 400 nm, as a rule are up to 50 micrometers long or in same cases longer, and which span between the cells. The invention further relates to a method wherein the organelle transport between the cells is investigated.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: January 8, 2008
    Assignee: Stiftelsen Universitetsforskning Bergen
    Inventors: Hans-Hermann Gerdes, Amin Rustom
  • Patent number: 7312047
    Abstract: The present invention relates to the use of an air-liquid interface culture model using asthmatic bronchial epithelial cells, which exhibit impaired epithelial barrier function. It is proposed to use asthmatic epithelial cultures, in the absence of added Th2 or proinflammatory cytokines such as IL-13, as an in vitro model to screen for agents that can act to improve impaired asthmatic epithelial barrier function. Such agents may have therapeutic utility in asthma patients.
    Type: Grant
    Filed: May 24, 2005
    Date of Patent: December 25, 2007
    Assignee: University of Southampton
    Inventors: Sarah M. Puddicombe, Donna Elizabeth Davies, Stephen Holgate
  • Patent number: 7294476
    Abstract: Several lines of evidence have shown a role for the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway in the development of spinal hyperalgesia. However, the roles of effectors for cGMP are not fully understood in the processing of pain in the spinal cord. cGMP-dependent protein kinase (PKG) I? but not PKGI? was localized in the neuronal bodies and processes, and was distributed primarily in the superficial laminae of the spinal cord. Intrathecal administration of an inhibitor of PKGI?, Rp-8-[(4-Chlorophenyl)thio]-cGMPS triethylamine, produces significant antinociception. Moreover, PKGI? protein expression was dramatically increased in the lumbar spinal cord after noxious stimulation. This upregulation of PKGI? expression was completely blocked not only by a neuronal NO synthase inhibitor, and a soluble guanylate cyclase inhibitor, but also by an N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801.
    Type: Grant
    Filed: August 10, 2005
    Date of Patent: November 13, 2007
    Assignee: The John Hopkins University
    Inventors: Roger A. Johns, Yuanxiang Tao
  • Patent number: 7291481
    Abstract: The release by trichomonads of a hydrolase that hydrolyzes a narrowly defined class of substrates at a low pH without interference from hydrolases that are unrelated to trichomoniasis is the basis for a selective diagnostic assay for trichomoniasis that measures hydrolysis of any of these substrates by vaginal fluid at a low pH. Selective assays for trichomoniasis are also obtained by removing particulate matter from a sample of vaginal fluid to extract a fraction devoid of particles greater than a selected size, and where desired, combining the extracted fraction with any of certain specified hydrolase inhibitors, then testing the fraction for enzymatic hydrolase activity. These qualities of trichomoniasis are the basis for a series of diagnostic tests and test devices that produce results that are detectable by visual and other means with a high degree of accuracy.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: November 6, 2007
    Assignee: Quidel Corporation
    Inventors: Paul J. Lawrence, Mark A. Hughes, Aulena Chaudhuri, Terrence J. Andreasen
  • Patent number: 7264921
    Abstract: The invention relates to particles for use in a scintillation proximity assays. In particular, the invention relates to particles for use in a scintillation proximity assay for detecting nitric oxide synthase activity in a sample. The invention also relates to a method of measuring nitric oxide synthase activity in a sample using these particles in a scintillation proximity assay. The invention further relates to methods using these particles to detect the presence of modulators of nitric oxide synthase activity.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: September 4, 2007
    Assignee: GE Healthcare UK Limited
    Inventors: Michael Roger Looker, David Williams
  • Patent number: 7244555
    Abstract: The present invention relates to methods of diagnosing and predicting organ transplant rejection. In particular, the present invention relates to the detection and prediction of kidney transplant rejection by detection of CXCR3 and CCL chemokines in urine. The present invention provides improved methods of diagnosing organ rejection and determining the efficacy of anti-rejection drugs.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: July 17, 2007
    Assignee: Renovak Inc
    Inventors: Huaizhong Hu, Alice Puchalski
  • Patent number: 7238494
    Abstract: Skin cholesterol is measured by applying an adhesive tape onto a selected area of the skin to adhere the tape to the selected skin area and stripping the tape off the selected skin area to obtain a sample representative of the outer stratum corneum layer of the skin, the sample adhering to the tape so as to have exposed skin constituents. The sample is assayed using a detector reagent that specifically binds to cholesterol and in addition has an indicator component that allows quantitation of the amount of cholesterol present in the exposed skin constituents.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: July 3, 2007
    Assignee: IMI International Medical Innovations, Inc.
    Inventors: Peter Horsewood, Robert Zawydiwski
  • Patent number: 7223864
    Abstract: The inventors have purified the fluorescent product in the hydroethidine-based supeorxide detection assays and further identified the product as 2-hydroxyethidium. Methods for synthesizing 2-hydroxyethidium and for detecting and quantifying superoxide are provided.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: May 29, 2007
    Assignee: MCW Research Foundation, Inc.
    Inventors: Balaraman Kalyanaraman, Hongtao Zhao
  • Patent number: 7217564
    Abstract: An object of the present invention is to provide a cytotoxic assay using a new established fish cell line. The invention attained according to the object is a cytotoxic assay, wherein an evaluation of toxicity of a specimen is performed on the basis of its toxicity to an established cell line originated from sturgeon, preferably a STIP-1 cell line (FERM BP-8421) and a STIP-3 cell line (FERM BP-8422). Furthermore, another object of the present invention is to provide a new established cell line expected to be used in the diagnosis of viral infection disease of sturgeon and so on. The invention attained according to the object is an established cell line originated from a sturgeon eyeball, particularly a STIP-1 cell line (FERM BP-8421) and a STIP-3 cell line (FERM BP-8422).
    Type: Grant
    Filed: November 23, 2005
    Date of Patent: May 15, 2007
    Assignee: Fujikin Incorporated
    Inventors: Shin-ichi Ono, Kiyoshi Hiraoka
  • Patent number: 7211410
    Abstract: An analytical fluorometric method and a kit for use in such method are disclosed for assessing the presence of alkaline sphingomyelinase (SMase) in the stool of a patient in need of such an assessment since alkaline SMase is a marker of serious pathological states, such as colon cancer.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: May 1, 2007
    Assignee: VSL Pharmaceuticals, Inc.
    Inventor: Claudio De Simone